We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
- Authors
Burstein, Harold J; Elias, Anthony D; Rugo, Hope S; Cobleigh, Melody A; Wolff, Antonio C; Eisenberg, Peter D; Lehman, Mary; Adams, Bonne J; Bello, Carlo L; DePrimo, Samuel E; Baum, Charles M; Miller, Kathy D
- Abstract
Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, stem cell factor receptor (KIT), and colony-stimulating factor-1 receptor. This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 11, p1810
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.14.5375